ARCHIVES

Regulatory Approvals: FDA expanded the approved use of Cyramza to include metastatic NSCLC

This article is from The Cancer Letter archive.

Vol. 40 No. 47 | December 19, 2014

Download PDF Visit The Full Archive

Related Articles

NCAB Considering Concept Review Of Large, Expensive Investigator Initiated Proposals

February 16, 1990

NCI To Fund More SPORE Grants In FY95 Recopetition

March 11, 1994

ASCO: Anastrozole Adds Treatment Option, But Tamoxifen Remains Standard

September 13, 2002

Recommendation By Patients; report Of Protocol Committee

August 9, 1996

ASCO Annual Meeting Abstracts Posted Online

May 28, 2010

Preliminary Action Plan Seeks Consumer Representation

January 7, 1994